Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Deucrictibant for Prophylaxis Against Angioedema Attacks in Hereditary Angioedema
NCT06679881Phase 3Enrolling by invitation
- Sponsor
- Pharvaris
- Start
- Feb 2025
- Primary completion
- Dec 2028
- Modality
- Small Molecules
- Countries
- 23
01
Overview
Phase 3, open-label, single-arm trial of deucrictibant in hereditary angioedema (HAE), sponsored by Pharvaris. Primary endpoints: Treatment-Emergent Adverse Events at 240 weeks, Change in heart rate at 240 weeks and 6 more. Started Feb 2025; status: enrolling by invitation.
02
Drugs
deucrictibant
03
Conditions
hereditary angioedema (HAE)
Beyond the preview
Go deeper on NCT06679881.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06679881.